Report Detail
Purchase Price: $4,750.00
Drug Delivery: Inhalation Devices
The 2023 combined prevalence of asthma and COPD in the countries covered by this report was approximately 72.7 million, with asthma accounting for an estimated three-quarters of cases and COPD accounting for the remaining quarter. In 2023, combined sales of inhaled asthma and COPD therapies in the countries covered by this analysis totaled more than $10bn. Market drivers include the increasing prevalence of asthma and COPD due to the growing/aging population, the introduction and increase in usage of triple-combination therapies (which eliminate the need for patients to use multiple devices for disease control), and the implementation of product lifecycle maintenance strategies (e.g., the launch of existing medications with newer digital inhalers). Limiters to this market include generic competition for blockbuster drug/device combos, reduced monotherapy sales as double- and triple-combination products supplant them to some extent, and competition from non-inhaled therapies such as biologics. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for inhaled asthma and COPD treatment drug/device combination products. Countries covered by this report include the US, Japan, and the five major European markets (France, Germany, Italy, Spain, and the UK). The forecast range for this report is 2023–28.
Related Medtech Insight articles:
- Q&A Guidance Clarifies Human Factors Testing For Combination Products
- DTA Panel Discusses Future Of Digital Therapeutics, Obstacles To Wider Adoption
- ‘Training People To Be Healthier’: Digital Therapeutics Programmed For Growth
- Subscribe to Medtech Insight to view these articles and more!
If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].
